Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099981 · ClinicalTrials.gov registry record · Phase 1
Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02099981 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 34 participants.
The verdict
NCT02099981, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
Diabetic retinopathy is the leading cause of blindness in the developed world. The causes of the disease are poorly understood. One of the earliest changes that occur in the retinas of diabetic patients, well before overt retinopathy is observed, is a reduction in light-evoked increases in blood flow in retinal vessels. The loss of this vascular response may lead to retinal hypoxia and it has been suggested that hypoxia could be a principal cause of diabetic retinopathy. The long-term goals of this project are to determine whether decreased blood flow in diabetic patients and the resulting retinal hypoxia contributes to the development of diabetic retinopathy and whether restoration of normal blood flow in diabetic patients slows or prevents the development of retinopathy.
Interventions
- DRUG Aminoguanidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099981
The ClinicalTrials.gov registry entry for NCT02099981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aminoguanidine is the first listed.
NCT02099981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02099981 about?
NCT02099981 is a clinical study titled "Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients". Diabetic retinopathy is the leading cause of blindness in the developed world. The causes of the disease are poorly understood. One of the earliest changes that occur in the retinas of diabetic patients, well before overt retinopathy is observed, is a reduction in light-evoked increases in blood flo...
What is the current status of trial NCT02099981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-07. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02099981?
The interventions under investigation include: Aminoguanidine (DRUG).
Who is sponsoring clinical trial NCT02099981?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.